The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Peptide Vaccine-Global Market Insights and Sales Trends 2024
Synopsis
Peptide vaccines include one or more short or long amino acids sequences, as an antigen combined with a vaccine adjuvant. Thus they fall in the broad category of defined antigen vaccines, along with the vaccines using proteins, protein sub units, DNA and RNA. They remain the most immunogenic approaches based on the measures of T-cell responses. Peptide immunogenicity is influenced by the way in which peptides are presented to the immune system, underscoring the need for multifunctional delivery systems that couple antigen and adjuvant into a single construct.
The global Peptide Vaccine market size is expected to reach US$ 4935.8 million by 2029, growing at a CAGR of 4.3% from 2023 to 2029. The market is mainly driven by the significant applications of Peptide Vaccine in various end use industries. The expanding demands from the Prostate Cancer, Breast Cancer, Gastric Cancer and Lung Cancer, are propelling Peptide Vaccine market. Solution Phase Synthesis (SPS), one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Solid Phase Peptide Synthesis (SPPS) segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Objectives
This report provides market insight on the different segments, by manufacturers, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Peptide Vaccine, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Peptide Vaccine market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Peptide Vaccine market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Peptide Vaccine sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Peptide Vaccine covered in this report include Anergis, Antigen Express, Apitope Technology, Artificial Cell Technologies, Benovus Bio, Celgene Corporation, Immatics biotechnologies, Merck and ImmunoCellular Therapeutics, etc.
The global Peptide Vaccine market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Anergis
Antigen Express
Apitope Technology
Artificial Cell Technologies
Benovus Bio
Celgene Corporation
Immatics biotechnologies
Merck
ImmunoCellular Therapeutics
ISA Pharmaceuticals
Lytix Biopharma
Spotlight Innovation
OncoTherapy Science
Peptech
Pharmasyntez
Sumitomo Dainippon Pharma
TapImmune
Targovax
Global Peptide Vaccine market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Peptide Vaccine market, Segment by Type:
Solution Phase Synthesis (SPS)
Solid Phase Peptide Synthesis (SPPS)
Global Peptide Vaccine market, by Application
Prostate Cancer
Breast Cancer
Gastric Cancer
Lung Cancer
Pancreatic Cancer
Others
Core Chapters
Chapter One: Introduces the study scope of this report, executive summary of market segments by Type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Two: Detailed analysis of Peptide Vaccine manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Three: Sales, revenue of Peptide Vaccine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.
Chapter Four: Introduces market segments by Application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Five, Six, Seven, Eight and Nine: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.
Chapter Ten: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter Eleven: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics. Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Analysis of sales channel, distributors and customers.
Chapter Thirteen: Research Findings and Conclusion.
Peptide vaccines include one or more short or long amino acids sequences, as an antigen combined with a vaccine adjuvant. Thus they fall in the broad category of defined antigen vaccines, along with the vaccines using proteins, protein sub units, DNA and RNA. They remain the most immunogenic approaches based on the measures of T-cell responses. Peptide immunogenicity is influenced by the way in which peptides are presented to the immune system, underscoring the need for multifunctional delivery systems that couple antigen and adjuvant into a single construct.
The global Peptide Vaccine market size is expected to reach US$ 4935.8 million by 2029, growing at a CAGR of 4.3% from 2023 to 2029. The market is mainly driven by the significant applications of Peptide Vaccine in various end use industries. The expanding demands from the Prostate Cancer, Breast Cancer, Gastric Cancer and Lung Cancer, are propelling Peptide Vaccine market. Solution Phase Synthesis (SPS), one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Solid Phase Peptide Synthesis (SPPS) segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Objectives
This report provides market insight on the different segments, by manufacturers, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Peptide Vaccine, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Peptide Vaccine market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Peptide Vaccine market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Peptide Vaccine sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Peptide Vaccine covered in this report include Anergis, Antigen Express, Apitope Technology, Artificial Cell Technologies, Benovus Bio, Celgene Corporation, Immatics biotechnologies, Merck and ImmunoCellular Therapeutics, etc.
The global Peptide Vaccine market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Anergis
Antigen Express
Apitope Technology
Artificial Cell Technologies
Benovus Bio
Celgene Corporation
Immatics biotechnologies
Merck
ImmunoCellular Therapeutics
ISA Pharmaceuticals
Lytix Biopharma
Spotlight Innovation
OncoTherapy Science
Peptech
Pharmasyntez
Sumitomo Dainippon Pharma
TapImmune
Targovax
Global Peptide Vaccine market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Peptide Vaccine market, Segment by Type:
Solution Phase Synthesis (SPS)
Solid Phase Peptide Synthesis (SPPS)
Global Peptide Vaccine market, by Application
Prostate Cancer
Breast Cancer
Gastric Cancer
Lung Cancer
Pancreatic Cancer
Others
Core Chapters
Chapter One: Introduces the study scope of this report, executive summary of market segments by Type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Two: Detailed analysis of Peptide Vaccine manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Three: Sales, revenue of Peptide Vaccine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.
Chapter Four: Introduces market segments by Application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Five, Six, Seven, Eight and Nine: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.
Chapter Ten: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter Eleven: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics. Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Analysis of sales channel, distributors and customers.
Chapter Thirteen: Research Findings and Conclusion.
Index1 Peptide Vaccine Market Overview
1.1 Peptide Vaccine Product Overview
1.2 Peptide Vaccine Market Segment by Type
1.2.1 Solution Phase Synthesis (SPS)
1.2.2 Solid Phase Peptide Synthesis (SPPS)
1.3 Global Peptide Vaccine Market Size by Type
1.3.1 Global Peptide Vaccine Market Size Overview by Type (2018-2029)
1.3.2 Global Peptide Vaccine Historic Market Size Review by Type (2018-2023)
1.3.3 Global Peptide Vaccine Forecasted Market Size by Type (2024-2029)
1.4 Key Regions Market Size Segment by Type
1.4.1 North America Peptide Vaccine Sales Breakdown by Type (2018-2023)
1.4.2 Europe Peptide Vaccine Sales Breakdown by Type (2018-2023)
1.4.3 Asia-Pacific Peptide Vaccine Sales Breakdown by Type (2018-2023)
1.4.4 Latin America Peptide Vaccine Sales Breakdown by Type (2018-2023)
1.4.5 Middle East and Africa Peptide Vaccine Sales Breakdown by Type (2018-2023)
2 Global Peptide Vaccine Market Competition by Company
2.1 Global Top Players by Peptide Vaccine Sales (2018-2023)
2.2 Global Top Players by Peptide Vaccine Revenue (2018-2023)
2.3 Global Top Players by Peptide Vaccine Price (2018-2023)
2.4 Global Top Manufacturers Peptide Vaccine Manufacturing Base Distribution, Sales Area, Product Type
2.5 Peptide Vaccine Market Competitive Situation and Trends
2.5.1 Peptide Vaccine Market Concentration Rate (2018-2023)
2.5.2 Global 5 and 10 Largest Manufacturers by Peptide Vaccine Sales and Revenue in 2022
2.6 Global Top Manufacturers by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Peptide Vaccine as of 2022)
2.7 Date of Key Manufacturers Enter into Peptide Vaccine Market
2.8 Key Manufacturers Peptide Vaccine Product Offered
2.9 Mergers & Acquisitions, Expansion
3 Peptide Vaccine Status and Outlook by Region
3.1 Global Peptide Vaccine Market Size and CAGR by Region: 2018 VS 2022 VS 2029
3.2 Global Peptide Vaccine Historic Market Size by Region
3.2.1 Global Peptide Vaccine Sales in Volume by Region (2018-2023)
3.2.2 Global Peptide Vaccine Sales in Value by Region (2018-2023)
3.2.3 Global Peptide Vaccine Sales (Volume & Value) Price and Gross Margin (2018-2023)
3.3 Global Peptide Vaccine Forecasted Market Size by Region
3.3.1 Global Peptide Vaccine Sales in Volume by Region (2024-2029)
3.3.2 Global Peptide Vaccine Sales in Value by Region (2024-2029)
3.3.3 Global Peptide Vaccine Sales (Volume & Value), Price and Gross Margin (2024-2029)
4 Global Peptide Vaccine by Application
4.1 Peptide Vaccine Market Segment by Application
4.1.1 Prostate Cancer
4.1.2 Breast Cancer
4.1.3 Gastric Cancer
4.1.4 Lung Cancer
4.1.5 Pancreatic Cancer
4.1.6 Others
4.2 Global Peptide Vaccine Market Size by Application
4.2.1 Global Peptide Vaccine Market Size Overview by Application (2018-2029)
4.2.2 Global Peptide Vaccine Historic Market Size Review by Application (2018-2023)
4.2.3 Global Peptide Vaccine Forecasted Market Size by Application (2024-2029)
4.3 Key Regions Market Size Segment by Application
4.3.1 North America Peptide Vaccine Sales Breakdown by Application (2018-2023)
4.3.2 Europe Peptide Vaccine Sales Breakdown by Application (2018-2023)
4.3.3 Asia-Pacific Peptide Vaccine Sales Breakdown by Application (2018-2023)
4.3.4 Latin America Peptide Vaccine Sales Breakdown by Application (2018-2023)
4.3.5 Middle East and Africa Peptide Vaccine Sales Breakdown by Application (2018-2023)
5 North America Peptide Vaccine by Country
5.1 North America Peptide Vaccine Historic Market Size by Country
5.1.1 North America Peptide Vaccine Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
5.1.2 North America Peptide Vaccine Sales in Volume by Country (2018-2023)
5.1.3 North America Peptide Vaccine Sales in Value by Country (2018-2023)
5.2 North America Peptide Vaccine Forecasted Market Size by Country
5.2.1 North America Peptide Vaccine Sales in Volume by Country (2024-2029)
5.2.2 North America Peptide Vaccine Sales in Value by Country (2024-2029)
6 Europe Peptide Vaccine by Country
6.1 Europe Peptide Vaccine Historic Market Size by Country
6.1.1 Europe Peptide Vaccine Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
6.1.2 Europe Peptide Vaccine Sales in Volume by Country (2018-2023)
6.1.3 Europe Peptide Vaccine Sales in Value by Country (2018-2023)
6.2 Europe Peptide Vaccine Forecasted Market Size by Country
6.2.1 Europe Peptide Vaccine Sales in Volume by Country (2024-2029)
6.2.2 Europe Peptide Vaccine Sales in Value by Country (2024-2029)
7 Asia-Pacific Peptide Vaccine by Region
7.1 Asia-Pacific Peptide Vaccine Historic Market Size by Region
7.1.1 Asia-Pacific Peptide Vaccine Market Size Growth Rate (CAGR) by Region: 2018 VS 2022 VS 2029
7.1.2 Asia-Pacific Peptide Vaccine Sales in Volume by Region (2018-2023)
7.1.3 Asia-Pacific Peptide Vaccine Sales in Value by Region (2018-2023)
7.2 Asia-Pacific Peptide Vaccine Forecasted Market Size by Region
7.2.1 Asia-Pacific Peptide Vaccine Sales in Volume by Region (2024-2029)
7.2.2 Asia-Pacific Peptide Vaccine Sales in Value by Region (2024-2029)
8 Latin America Peptide Vaccine by Country
8.1 Latin America Peptide Vaccine Historic Market Size by Country
8.1.1 Latin America Peptide Vaccine Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
8.1.2 Latin America Peptide Vaccine Sales in Volume by Country (2018-2023)
8.1.3 Latin America Peptide Vaccine Sales in Value by Country (2018-2023)
8.2 Latin America Peptide Vaccine Forecasted Market Size by Country
8.2.1 Latin America Peptide Vaccine Sales in Volume by Country (2024-2029)
8.2.2 Latin America Peptide Vaccine Sales in Value by Country (2024-2029)
9 Middle East and Africa Peptide Vaccine by Country
9.1 Middle East and Africa Peptide Vaccine Historic Market Size by Country
9.1.1 Middle East and Africa Peptide Vaccine Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
9.1.2 Middle East and Africa Peptide Vaccine Sales in Volume by Country (2018-2023)
9.1.3 Middle East and Africa Peptide Vaccine Sales in Value by Country (2018-2023)
9.2 Middle East and Africa Peptide Vaccine Forecasted Market Size by Country
9.2.1 Middle East and Africa Peptide Vaccine Sales in Volume by Country (2024-2029)
9.2.2 Middle East and Africa Peptide Vaccine Sales in Value by Country (2024-2029)
10 Company Profiles
10.1 Anergis
10.1.1 Anergis Company Information
10.1.2 Anergis Introduction and Business Overview
10.1.3 Anergis Peptide Vaccine Sales, Revenue and Gross Margin (2018-2023)
10.1.4 Anergis Peptide Vaccine Products Offered
10.1.5 Anergis Recent Development
10.2 Antigen Express
10.2.1 Antigen Express Company Information
10.2.2 Antigen Express Introduction and Business Overview
10.2.3 Antigen Express Peptide Vaccine Sales, Revenue and Gross Margin (2018-2023)
10.2.4 Antigen Express Peptide Vaccine Products Offered
10.2.5 Antigen Express Recent Development
10.3 Apitope Technology
10.3.1 Apitope Technology Company Information
10.3.2 Apitope Technology Introduction and Business Overview
10.3.3 Apitope Technology Peptide Vaccine Sales, Revenue and Gross Margin (2018-2023)
10.3.4 Apitope Technology Peptide Vaccine Products Offered
10.3.5 Apitope Technology Recent Development
10.4 Artificial Cell Technologies
10.4.1 Artificial Cell Technologies Company Information
10.4.2 Artificial Cell Technologies Introduction and Business Overview
10.4.3 Artificial Cell Technologies Peptide Vaccine Sales, Revenue and Gross Margin (2018-2023)
10.4.4 Artificial Cell Technologies Peptide Vaccine Products Offered
10.4.5 Artificial Cell Technologies Recent Development
10.5 Benovus Bio
10.5.1 Benovus Bio Company Information
10.5.2 Benovus Bio Introduction and Business Overview
10.5.3 Benovus Bio Peptide Vaccine Sales, Revenue and Gross Margin (2018-2023)
10.5.4 Benovus Bio Peptide Vaccine Products Offered
10.5.5 Benovus Bio Recent Development
10.6 Celgene Corporation
10.6.1 Celgene Corporation Company Information
10.6.2 Celgene Corporation Introduction and Business Overview
10.6.3 Celgene Corporation Peptide Vaccine Sales, Revenue and Gross Margin (2018-2023)
10.6.4 Celgene Corporation Peptide Vaccine Products Offered
10.6.5 Celgene Corporation Recent Development
10.7 Immatics biotechnologies
10.7.1 Immatics biotechnologies Company Information
10.7.2 Immatics biotechnologies Introduction and Business Overview
10.7.3 Immatics biotechnologies Peptide Vaccine Sales, Revenue and Gross Margin (2018-2023)
10.7.4 Immatics biotechnologies Peptide Vaccine Products Offered
10.7.5 Immatics biotechnologies Recent Development
10.8 Merck
10.8.1 Merck Company Information
10.8.2 Merck Introduction and Business Overview
10.8.3 Merck Peptide Vaccine Sales, Revenue and Gross Margin (2018-2023)
10.8.4 Merck Peptide Vaccine Products Offered
10.8.5 Merck Recent Development
10.9 ImmunoCellular Therapeutics
10.9.1 ImmunoCellular Therapeutics Company Information
10.9.2 ImmunoCellular Therapeutics Introduction and Business Overview
10.9.3 ImmunoCellular Therapeutics Peptide Vaccine Sales, Revenue and Gross Margin (2018-2023)
10.9.4 ImmunoCellular Therapeutics Peptide Vaccine Products Offered
10.9.5 ImmunoCellular Therapeutics Recent Development
10.10 ISA Pharmaceuticals
10.10.1 ISA Pharmaceuticals Company Information
10.10.2 ISA Pharmaceuticals Introduction and Business Overview
10.10.3 ISA Pharmaceuticals Peptide Vaccine Sales, Revenue and Gross Margin (2018-2023)
10.10.4 ISA Pharmaceuticals Peptide Vaccine Products Offered
10.10.5 ISA Pharmaceuticals Recent Development
10.11 Lytix Biopharma
10.11.1 Lytix Biopharma Company Information
10.11.2 Lytix Biopharma Introduction and Business Overview
10.11.3 Lytix Biopharma Peptide Vaccine Sales, Revenue and Gross Margin (2018-2023)
10.11.4 Lytix Biopharma Peptide Vaccine Products Offered
10.11.5 Lytix Biopharma Recent Development
10.12 Spotlight Innovation
10.12.1 Spotlight Innovation Company Information
10.12.2 Spotlight Innovation Introduction and Business Overview
10.12.3 Spotlight Innovation Peptide Vaccine Sales, Revenue and Gross Margin (2018-2023)
10.12.4 Spotlight Innovation Peptide Vaccine Products Offered
10.12.5 Spotlight Innovation Recent Development
10.13 OncoTherapy Science
10.13.1 OncoTherapy Science Company Information
10.13.2 OncoTherapy Science Introduction and Business Overview
10.13.3 OncoTherapy Science Peptide Vaccine Sales, Revenue and Gross Margin (2018-2023)
10.13.4 OncoTherapy Science Peptide Vaccine Products Offered
10.13.5 OncoTherapy Science Recent Development
10.14 Peptech
10.14.1 Peptech Company Information
10.14.2 Peptech Introduction and Business Overview
10.14.3 Peptech Peptide Vaccine Sales, Revenue and Gross Margin (2018-2023)
10.14.4 Peptech Peptide Vaccine Products Offered
10.14.5 Peptech Recent Development
10.15 Pharmasyntez
10.15.1 Pharmasyntez Company Information
10.15.2 Pharmasyntez Introduction and Business Overview
10.15.3 Pharmasyntez Peptide Vaccine Sales, Revenue and Gross Margin (2018-2023)
10.15.4 Pharmasyntez Peptide Vaccine Products Offered
10.15.5 Pharmasyntez Recent Development
10.16 Sumitomo Dainippon Pharma
10.16.1 Sumitomo Dainippon Pharma Company Information
10.16.2 Sumitomo Dainippon Pharma Introduction and Business Overview
10.16.3 Sumitomo Dainippon Pharma Peptide Vaccine Sales, Revenue and Gross Margin (2018-2023)
10.16.4 Sumitomo Dainippon Pharma Peptide Vaccine Products Offered
10.16.5 Sumitomo Dainippon Pharma Recent Development
10.17 TapImmune
10.17.1 TapImmune Company Information
10.17.2 TapImmune Introduction and Business Overview
10.17.3 TapImmune Peptide Vaccine Sales, Revenue and Gross Margin (2018-2023)
10.17.4 TapImmune Peptide Vaccine Products Offered
10.17.5 TapImmune Recent Development
10.18 Targovax
10.18.1 Targovax Company Information
10.18.2 Targovax Introduction and Business Overview
10.18.3 Targovax Peptide Vaccine Sales, Revenue and Gross Margin (2018-2023)
10.18.4 Targovax Peptide Vaccine Products Offered
10.18.5 Targovax Recent Development
11 Upstream, Opportunities, Challenges, Risks and Influences Factors Analysis
11.1 Peptide Vaccine Key Raw Materials
11.1.1 Key Raw Materials
11.1.2 Key Raw Materials Price
11.1.3 Raw Materials Key Suppliers
11.2 Manufacturing Cost Structure
11.2.1 Raw Materials
11.2.2 Labor Cost
11.2.3 Manufacturing Expenses
11.3 Peptide Vaccine Industrial Chain Analysis
11.4 Peptide Vaccine Market Dynamics
11.4.1 Peptide Vaccine Industry Trends
11.4.2 Peptide Vaccine Market Drivers
11.4.3 Peptide Vaccine Market Challenges
11.4.4 Peptide Vaccine Market Restraints
12 Market Strategy Analysis, Distributors
12.1 Sales Channel
12.2 Peptide Vaccine Distributors
12.3 Peptide Vaccine Downstream Customers
13 Research Findings and Conclusion
14 Appendix
14.1 Research Methodology
14.1.1 Methodology/Research Approach
14.1.2 Data Source
14.2 Author Details
14.3 Disclaimer
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
